CoChat

A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors.

Tolcher, A. W., Baird, R. D., Patnaik, A., Moreno Garcia, V., Papadopoulos, K. P., Garrett, C. R., Olmos, D., Shannon, K. A., Zazulina, V., Rubin, E. H., Smith, I. C., Ryan, J., Smith, P. D., Taylor, A., Learoyd, M., Lupinacci, L., Yan, L., De Bono, J. S. · 2011 · Journal of Clinical Oncology
Cited by 35

The DOI matches its Crossref record.

Abstract

3004 Background: The PI3K-Akt and RAF/MEK/ERK pathways represent two of the most frequently activated growth factor signaling pathways in human cancer. Inhibition of both pathways could yield greater benefits than inhibiting either pathway alone. The objectives of this phase I study were to examine the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of the novel combination of MK-2206 with selumetinib. This investigational study represents a new approach to early-stage drug development with the collaboration of two pharmaceutical companies co-developing early stage targeted agent combinations (NCT01021748). Methods: Eligible patients with advanced solid tumors were treated with MK-2206 either every other day (QOD) or once weekly (QW), in combination with selumetinib administered continuously either once daily (QD) or twice daily (BID). Results: To date, 33 patients have been treated on five dose levels. In the MK-2206 QOD dosing schedule, dose-limiting Grade 3 macular skin rash was reported in 2/3 evaluable patients at MK-2206 45 mg QOD with selumetinib 75mg BID; the tolerable dose was MK-2206 45 mg QOD with selumetinib 75 mg QD. For QW MK-2206, dose-limiting acneiform rash (n=1), stomatitis (n=1) and detached retinal pigment epithelium (n=1) were observed in 3/7 evaluable patients treated at MK-2206 90 mg QW with selumetinib 75mg BID; dose reduction to MK-2206 90mg QW/ selumetinib 50 mg BID was not tolerated due to dose-limiting acneiform rash in 2/ 4 evaluable patients. An intermediate dose of MK-2206 90mg once weekly with selumetinib 75mg QD was tolerable. Preliminary assessment of PK/PD data suggest no apparent drug-drug interactions with the PK profile of each drug administered in this combination. Conclusions: MK2206 at 45 mg QOD, or 90 mg QW is well tolerated in combination with selumetinib 75 mg QD in patients with advanced cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.29.15_suppl.3004

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 35

Metadata

Authors
Tolcher, A. W., Baird, R. D., Patnaik, A., Moreno Garcia, V., Papadopoulos, K. P., Garrett, C. R., Olmos, D., Shannon, K. A., Zazulina, V., Rubin, E. H., Smith, I. C., Ryan, J., Smith, P. D., Taylor, A., Learoyd, M., Lupinacci, L., Yan, L., & De Bono, J. S.
Venue
Journal of Clinical Oncology
Published
2011-05-20
Volume
29
Issue
15_suppl
Pages
3004-3004
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4242522656
Cited by
35
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. https://app.cochat.ai/papers/10.1200/jco.2011.29.15_suppl.3004
The paper
Tolcher, A. W., Baird, R. D., Patnaik, A., Moreno Garcia, V., Papadopoulos, K. P., Garrett, C. R., Olmos, D., Shannon, K. A., Zazulina, V., Rubin, E. H., Smith, I. C., Ryan, J., Smith, P. D., Taylor, A., Learoyd, M., Lupinacci, L., Yan, L., & De Bono, J. S. (2011). A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.29.15_suppl.3004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.